News in Brief
Pharmacology - Jan 21
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
wire - news in brief
Category
Results 351 - 393 of 393.
European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer - an aggressive and difficult-to-treat disease Approval based on the
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer - an aggressive and difficult-to-treat disease Approval based on the
Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq
This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000 patients around the
This launch represents an important step in Roche's personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000 patients around the
Federal Council aims for a climate-neutral Switzerland by 2050
Under the Paris Agreement on Climate Change, Switzerland has undertaken to halve its greenhouse gas emissions by 2030 compared with 1990 levels.
Under the Paris Agreement on Climate Change, Switzerland has undertaken to halve its greenhouse gas emissions by 2030 compared with 1990 levels.
People and technology ensured inspiration at Zurich’s main station
Cybathlon feeling and plenty of enthusiasm at Zurich's main station ' numerous visitors came to join the competition yesterday as people with disabilities used the latest assistive technology to overcome a challenging obstacle course.
Cybathlon feeling and plenty of enthusiasm at Zurich's main station ' numerous visitors came to join the competition yesterday as people with disabilities used the latest assistive technology to overcome a challenging obstacle course.
There is an ongoing debate in society about sex education. Now a study is a combination of parents and school.
EPFL Professor Michael Grätzel is ranked #1 in a list of 100,000 top scientists across all fields. The ranking method is a based on new, more accurate standardized citation metrics developed by scientists led by Stanford University.
With the help of a 3D printed salt template, ETH researchers have succeeded in producing magnesium scaffolds with structured porosity that are suitable for bioresorbable bone implants. For the treatment of complex bone fractures or even missing bone parts, surgeons typically deploy metal implants. In this context, an attractive alternative to the traditional materials like bioinert titanium are biodegradable magnesium and its alloys.
Summer series - Student projects. For her Master's project, Emylou Jaquier decided to tackle the growing problem of plastic waste.
New tools for malaria prevention and treatment are required to eradicate malaria in the foreseeable future, according to the World Health Organization (WHO).
Time is a fundamental dimension of human existence and comes in many forms. Using a comparative approach, philosopher and physicist Norman Sieroka looks at what distinguishes them, using time travel and music.
ETH spin-off Spectroplast has developed a method to make silicone products using a 3D printer. The young company now plans to bring to market customised medical products such as hearing aids, breast prosthesis for breast cancer patients and eventually even artificial heart valves.
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
PARAGON-HF trial will provide Entresto (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF) New PROVE-HF and EVALUATE-HF studies will highlight Entresto's direct impact on the heart in heart failure with reduced ejection fraction (HFrEF) New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilizatio
PARAGON-HF trial will provide Entresto (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF) New PROVE-HF and EVALUATE-HF studies will highlight Entresto's direct impact on the heart in heart failure with reduced ejection fraction (HFrEF) New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilizatio
Internal combustion engines require valves to aspirate and discharge gases. Engine designers require a high degree of flexibility to improve efficiency, reduce pollutants and optimize the use of renewable fuels.
Deubiquitinases (DUBs) play a general role removing protein-degrading ubiquitins throughout the cell and are not typically known for specificity. Analyzing the two protein complexes BRISC and BRCA1-A, which have the same DUB core but play different roles in human biology, the Thomä group - in a collaboration with the Novartis Institutes for BioMedical Research (NIBR) - showed that DUBs can have diversified targeting and regulatory functions.
FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
Prestigious grants from the USA go to two Bernese researchers: the biomedical scientists Marianna Kruithof-de Julio and Robert Rieben were the only researchers in Switzerland to receive a grant under
13 substances were detected for the first time in groundwater, 15 were found in concentrations above 100 ng/L. This is the threshold value for pesticides under the Water Protection Ordinance. The researchers are particularly targeting metabolites of chlorothalonil, a product used against fungal attack in cereal, vegetable, wine and ornamental plant cultivation.
Over the next three years, researchers from the Vrije Universiteit Brussel, University of Cambridge, École Supérieure de Physique et de Chimie Industrielles de la ville de Paris (ESPCI-Paris) and Empa will be working together with the Dutch Polymer manufacturer SupraPolix on the next generation of robots: (soft) robots that 'feel pain' and heal themselves.
Novartis stands behind Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.
Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.
The supervision of doctoral students has long been the subject of intense debate both within and beyond the walls of our university.
Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc.
(Summer Series): Mathieu Clavel, a master's student in the College of Humanities (CDH) Digital Humanities Institute, is bringing musical heritage from Afghanistan to life using tools from data science and virtual reality.
The ETH Zurich Zentrum and Hönggerberg campuses are not just the study and office spaces of the 30,000 members of ETH: they are also home to a variety of animals and plants.
News in Brief
Pharmacology - Jan 21
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma